CA2760348A1 - Method for identifying inhibitors against dengue virus - Google Patents
Method for identifying inhibitors against dengue virus Download PDFInfo
- Publication number
- CA2760348A1 CA2760348A1 CA2760348A CA2760348A CA2760348A1 CA 2760348 A1 CA2760348 A1 CA 2760348A1 CA 2760348 A CA2760348 A CA 2760348A CA 2760348 A CA2760348 A CA 2760348A CA 2760348 A1 CA2760348 A1 CA 2760348A1
- Authority
- CA
- Canada
- Prior art keywords
- cells
- dengue virus
- virus
- dengue
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/66—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving luciferase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/18—Togaviridae; Flaviviridae
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/902—Oxidoreductases (1.)
- G01N2333/90241—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Physics & Mathematics (AREA)
- Zoology (AREA)
- Pathology (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention concerns a method for identifying inhibitors against dengue virus subtypes 1, 2, 3 or 4 and its use in a high throughput mode, wherein luminescence produced by luciferase enzyme and luciferase substrate is measured.
Description
Method for identifying inhibitors against Dengue Virus The present invention relates to a method for identifying inhibitors against dengue virus subtypes 1, 2, 3 or 4 and its use in a high throughput mode.
The family Flaviviridae includes approximately 60 enveloped, positive-strand RNA viruses, most of which are transmitted by an insect vector. Many members of this family cause significant public health problems in different regions of the world. The genomes of all flaviviruses sequenced thus far have 1o the same gene order: 5'-C-preM-E-NS1-NS2A-NS2B-NS3-NS4A-NS4B-NS5-3' in which the first three genes code for the structural proteins the capsid (C), the precursor to the membrane protein (prM) and the envelope protein (E).
Dengue is a mosquito-borne viral disease which occurs in tropical and sub-tropical regions throughout the world. Dengue is characterized by fever, rash, severe headache and joint pain. Its mortality rate is low. However, over the past few decades, a more severe form of dengue, characterized by hemorrhage and shock (dengue hemorrhagic fever/dengue shock syndrome;
DHF/DSS) has been observed with increasing frequency in children and young adults. DHF/DSS occurs most often during dengue virus infection in individuals previously infected with another dengue virus serotype. This has led to the suggestion that immune enhancement of viral replication plays a role in the pathogenesis of the more severe form of disease.
Dengue epidemics are a major public health problem in many tropical and subtropical areas where the vector mosquito species are abundant. Control of dengue fever and DHF/DSS is a major concern of public health. Consequently, the WHO has designated the dengue viruses as a high priority target for accelerated research and vaccine development. Despite 40 years of intensive 3o research, safe and effective vaccines for dengue virus disease are not available.
Soon after their isolation in 1944, dengue viruses were passaged repeatedly in mouse brain, resulting in the selection of mouse neurovirulent mutants.
Interestingly, studies performed in volunteers showed that mouse brain-adapted neurovirulent mutants of three strains of type 1 or type 2 dengue viruses were attenuated, but still immunogenic for humans. However, the
The family Flaviviridae includes approximately 60 enveloped, positive-strand RNA viruses, most of which are transmitted by an insect vector. Many members of this family cause significant public health problems in different regions of the world. The genomes of all flaviviruses sequenced thus far have 1o the same gene order: 5'-C-preM-E-NS1-NS2A-NS2B-NS3-NS4A-NS4B-NS5-3' in which the first three genes code for the structural proteins the capsid (C), the precursor to the membrane protein (prM) and the envelope protein (E).
Dengue is a mosquito-borne viral disease which occurs in tropical and sub-tropical regions throughout the world. Dengue is characterized by fever, rash, severe headache and joint pain. Its mortality rate is low. However, over the past few decades, a more severe form of dengue, characterized by hemorrhage and shock (dengue hemorrhagic fever/dengue shock syndrome;
DHF/DSS) has been observed with increasing frequency in children and young adults. DHF/DSS occurs most often during dengue virus infection in individuals previously infected with another dengue virus serotype. This has led to the suggestion that immune enhancement of viral replication plays a role in the pathogenesis of the more severe form of disease.
Dengue epidemics are a major public health problem in many tropical and subtropical areas where the vector mosquito species are abundant. Control of dengue fever and DHF/DSS is a major concern of public health. Consequently, the WHO has designated the dengue viruses as a high priority target for accelerated research and vaccine development. Despite 40 years of intensive 3o research, safe and effective vaccines for dengue virus disease are not available.
Soon after their isolation in 1944, dengue viruses were passaged repeatedly in mouse brain, resulting in the selection of mouse neurovirulent mutants.
Interestingly, studies performed in volunteers showed that mouse brain-adapted neurovirulent mutants of three strains of type 1 or type 2 dengue viruses were attenuated, but still immunogenic for humans. However, the
-2-mutants were not developed further as candidate vaccine strains because of concern for mouse brain antigens in the vaccine preparations. Since that time, virus mutants that: (i) exhibited the small plaque size phenotype, and/or (ii) were temperature sensitive, and/or (iii) were adapted to cell cultures derived from an unnatural host (i.e., host range mutants), have been selected and evaluated as candidates for inclusion in a live attenuated virus vaccine.
However, despite 25 years of such efforts, safe, effective dengue vaccines are still not available for general use. Inactivated whole dengue virus vaccines have been shown to be insufficiently immunogenic. Live virus vaccines 1o attenuated by serial passage in cell culture have suffered from genetic instability under attenuation or poor immunogenicity.
The four serotypes of dengue viruses (type 1 to type 4) are distinguishable by plaque reduction neutralization using serotype-specific monoclonal antibodies and by less specific tests using polyclonal sera. The existence of serotypes was first discovered during early studies in human volunteers, which showed that infection with one dengue serotype induced durable homotypic immunity, whereas heterotypic immunity lasted only 3 to 5 months. An effective dengue vaccine that contains all four serotypes in order to induce broad immunity to dengue viruses in general would help to preclude the occurrence of DHF/DSS.
The complete nucleotide sequences have been determined for all four dengue virus serotypes (Mackow, E. et al. (1987) Virology 159:217-228; Zhao, B. et al.
(1986) Virology 155:77-88; Osatomi, K. & Sumiyoshi, H. (1990) Virology 176:643-647; Irie, A. et al. (1989) Gene 75:197-211; Mason, P. W. et al.
(1987) Virology 161:262-267; Hahn, Y. S. et al. (1988) Virology 162:167-180). The results of these studies indicate that the four dengue virus serotypes share a common genome organization. The genome of the dengue type 4 Caribbean strain 814669 was found to contain 10646 nucleotides (Mackow, E. et al.
(1987) Virology 159:217-228; Zhao, B. et al. (1986) Virology 155:77-88). The first 101 nucleotides at the 5' end and the last 384 at the 3' end are non-coding regions. The remaining sequence codes for a 3386 amino-acid polyprotein which includes the three structural proteins, namely, capsid (C), premembrane (prM), and envelope (E), at its N-terminus, followed by seven non-structural proteins in the order, provided above, that is consistent with all Flavivirus genomes identified thus far. The polyprotein is processed to generate 11 or more viral proteins by cell signal peptidase(s) and by viral proteases (Markoff,
However, despite 25 years of such efforts, safe, effective dengue vaccines are still not available for general use. Inactivated whole dengue virus vaccines have been shown to be insufficiently immunogenic. Live virus vaccines 1o attenuated by serial passage in cell culture have suffered from genetic instability under attenuation or poor immunogenicity.
The four serotypes of dengue viruses (type 1 to type 4) are distinguishable by plaque reduction neutralization using serotype-specific monoclonal antibodies and by less specific tests using polyclonal sera. The existence of serotypes was first discovered during early studies in human volunteers, which showed that infection with one dengue serotype induced durable homotypic immunity, whereas heterotypic immunity lasted only 3 to 5 months. An effective dengue vaccine that contains all four serotypes in order to induce broad immunity to dengue viruses in general would help to preclude the occurrence of DHF/DSS.
The complete nucleotide sequences have been determined for all four dengue virus serotypes (Mackow, E. et al. (1987) Virology 159:217-228; Zhao, B. et al.
(1986) Virology 155:77-88; Osatomi, K. & Sumiyoshi, H. (1990) Virology 176:643-647; Irie, A. et al. (1989) Gene 75:197-211; Mason, P. W. et al.
(1987) Virology 161:262-267; Hahn, Y. S. et al. (1988) Virology 162:167-180). The results of these studies indicate that the four dengue virus serotypes share a common genome organization. The genome of the dengue type 4 Caribbean strain 814669 was found to contain 10646 nucleotides (Mackow, E. et al.
(1987) Virology 159:217-228; Zhao, B. et al. (1986) Virology 155:77-88). The first 101 nucleotides at the 5' end and the last 384 at the 3' end are non-coding regions. The remaining sequence codes for a 3386 amino-acid polyprotein which includes the three structural proteins, namely, capsid (C), premembrane (prM), and envelope (E), at its N-terminus, followed by seven non-structural proteins in the order, provided above, that is consistent with all Flavivirus genomes identified thus far. The polyprotein is processed to generate 11 or more viral proteins by cell signal peptidase(s) and by viral proteases (Markoff,
-3-L. (1989) J. Virol, 63:3345-3352; Falgout, B. et al. (1989) J. Virol, 63:1852-1860; Falgout, B. et al. (1991) J. Virol. 65:2467-2476; Hori, H. & Lai, C. J.
(1990) J. Virol. 64:4573-4577).
Since lacking a vaccine to combat dengue virus and its further spread and infection throughout the world population, a high medical need exists to have small chemical molecules, such as chemical compounds, available which could inhibit dengue virus serotypes 1-4.
1o In order to be able to find those small chemical molecules a screening effort is definitely needed to test several thousands and millions of chemical molecules present in a compound library for their potential application in inhibiting dengue virus replication and expression.
Such a screening effort can only be accomplished with a good, fast and reliable high throughput screening assay wherein numerous of chemical compounds can be tested and analyzed in a high speed module.
The current invention relates to a method for identifying inhibitors against dengue viruses serotypes 1, 2, 3 or 4 by screening chemical compounds or chemical compound libraries comprising:
a) bringing about 1000 to 2000 Vero cells or Huh 7.5 cells into contact with a chemical compound, b) adding dengue virus to said cells and chemical compound of step a), c) incubating said cells, chemical compound and virus of step b) at 37 C
until viral cytopathic effect (CPE) in the virus control reaches about 100%, d) adding luciferase enzyme and luciferase substrate to the cells, compound, virus, and measuring thereafter the luminescence and calculate the EC50 value which is a measure for the inhibitory activity of the compound against dengue virus.
In the above method when dengue virus subtype 2 is used and tested for, the preferred amount of Vero cells is about 1500, while when dengue virus subtypes 1, 3 or 4 are used and tested for, the preferred cells are the so-called Huh 7.5 cells .
(1990) J. Virol. 64:4573-4577).
Since lacking a vaccine to combat dengue virus and its further spread and infection throughout the world population, a high medical need exists to have small chemical molecules, such as chemical compounds, available which could inhibit dengue virus serotypes 1-4.
1o In order to be able to find those small chemical molecules a screening effort is definitely needed to test several thousands and millions of chemical molecules present in a compound library for their potential application in inhibiting dengue virus replication and expression.
Such a screening effort can only be accomplished with a good, fast and reliable high throughput screening assay wherein numerous of chemical compounds can be tested and analyzed in a high speed module.
The current invention relates to a method for identifying inhibitors against dengue viruses serotypes 1, 2, 3 or 4 by screening chemical compounds or chemical compound libraries comprising:
a) bringing about 1000 to 2000 Vero cells or Huh 7.5 cells into contact with a chemical compound, b) adding dengue virus to said cells and chemical compound of step a), c) incubating said cells, chemical compound and virus of step b) at 37 C
until viral cytopathic effect (CPE) in the virus control reaches about 100%, d) adding luciferase enzyme and luciferase substrate to the cells, compound, virus, and measuring thereafter the luminescence and calculate the EC50 value which is a measure for the inhibitory activity of the compound against dengue virus.
In the above method when dengue virus subtype 2 is used and tested for, the preferred amount of Vero cells is about 1500, while when dengue virus subtypes 1, 3 or 4 are used and tested for, the preferred cells are the so-called Huh 7.5 cells .
-4-The MOI (Multiplicity of Infection) in the method when dengue virus subtype 2 is used and tested for is 0.1, 0.5 or 1.0, while preferably an MOI is used of 0.1.
The MOI (Multiplicity of Infection) in the method when dengue virus subtype 1, 3 or 4 is used and tested for, falls in the range of 1.0 and 10.0, but preferably is 1.0 or 5Ø
In the method according to the invention the incubation of the cells (Vero or Huh 7.5) together with a chemical compound and the dengue virus subtype tested for, occurs till a 100% cytopathic effect (CPE) has been obtained in the 1o virus control. The timing to obtain such CPE could run for 5 or 6 days at incubation.
The preferred substrate for the luciferase enzyme is D-Luciferin, while the method according to the invention can easily be adapted and used in a high throughput mode to test numerous amounts of compounds present in a chemical library.
In the present invention, the term "inhibitor" is used to refer to any chemical entity, such as chemical compound, small molecule, peptide, protein and the like, which inhibit the growth, replication and/or proliferation of dengue virus subtype 1, 2 , 3 or 4.
The term "Vero cells" and its respective cell line refer to the cell line which is derived from kidney epithelial cells of the African Green Monkey. The cell line was established in 1962 by Japanese scientists. (see Yasumura Y, Kawakita M
(1963). "The research for the SV40 by means of tissue culture technique".
Nippon Rinsho 21 (6): 1201-1219.) The term "Huh 7.5 cells" refers to those cells as a subline derived from Huh-7 3o hepatoma cells (Blight K J, McKeating J A, Rice C M. J Virol. 2002;76:13001-13014.) The ATPLiteTM system (Perkin-Elmer) is an Adenosine TriPhosphate (ATP) monitoring system based on firefly (Photinus pyralis) luciferase. This luminescence assay is an alternative to colorimetric, fluorometric and radioisotopic assays for the quantitative evaluation of proliferation and cytotoxicity of cultured mammalian cells. ATP monitoring can be used to
The MOI (Multiplicity of Infection) in the method when dengue virus subtype 1, 3 or 4 is used and tested for, falls in the range of 1.0 and 10.0, but preferably is 1.0 or 5Ø
In the method according to the invention the incubation of the cells (Vero or Huh 7.5) together with a chemical compound and the dengue virus subtype tested for, occurs till a 100% cytopathic effect (CPE) has been obtained in the 1o virus control. The timing to obtain such CPE could run for 5 or 6 days at incubation.
The preferred substrate for the luciferase enzyme is D-Luciferin, while the method according to the invention can easily be adapted and used in a high throughput mode to test numerous amounts of compounds present in a chemical library.
In the present invention, the term "inhibitor" is used to refer to any chemical entity, such as chemical compound, small molecule, peptide, protein and the like, which inhibit the growth, replication and/or proliferation of dengue virus subtype 1, 2 , 3 or 4.
The term "Vero cells" and its respective cell line refer to the cell line which is derived from kidney epithelial cells of the African Green Monkey. The cell line was established in 1962 by Japanese scientists. (see Yasumura Y, Kawakita M
(1963). "The research for the SV40 by means of tissue culture technique".
Nippon Rinsho 21 (6): 1201-1219.) The term "Huh 7.5 cells" refers to those cells as a subline derived from Huh-7 3o hepatoma cells (Blight K J, McKeating J A, Rice C M. J Virol. 2002;76:13001-13014.) The ATPLiteTM system (Perkin-Elmer) is an Adenosine TriPhosphate (ATP) monitoring system based on firefly (Photinus pyralis) luciferase. This luminescence assay is an alternative to colorimetric, fluorometric and radioisotopic assays for the quantitative evaluation of proliferation and cytotoxicity of cultured mammalian cells. ATP monitoring can be used to
-5-assess the cytocidal, cytostatic and proliferative effects of a wide range of drugs, biological response modifiers and biological compounds. ATPLite is a true homogeneous high sensitivity ATP monitoring 1-step addition assay kit for the quantification of viable cells. The kit can be used for continuous process systems such as in-line systems in high throughput environments. These in-line systems do not require a long signal half-life since the time between addition of the reagent and reading the resulting luminescence is relatively short (minutes). The decrease of the luminescent light-output is approximately 150% after 30 minutes. This decrease is independent of cell numbers but may 1o differ between cell type and medium. The maximum cell number that can be applied has been determined to be 50,000 cells per well for 05-well and 12,500 cells per well for 384-well micro plates. Because the kit needs no stabilization of the luminescence signal, high throughput is preserved.
ATP is a marker for cell viability because it is present in all metabolically active cells and the concentration declines very rapidly when the cells undergo necrosis or apoptosis. The ATPlite 1 step assay system is based on the production of light caused by the reaction of ATP with added luciferase and D-luciferin.
This is illustrated in the following reaction scheme:
ATP + D-Luciferin + 02 + (Mg 2W + Luciferase enyme) 9 Oxyluciferin +
+ AMP + BBi + C02 + Light The emitted light is proportional to the ATP concentration within certain limits.
Materials and methods 1. Cells and viruses Vero cells (African green monkey kidney cells) were purchased from the 3o European Collection of Cell Cultures (ECACC) and cultured in Eagle's Minimum Essential Medium (MEM; Invitrogen) supplemented with 10% fetal calf serum (FCS; Cambrex, Belgium), 2 mM L-glutamine, and 0.04%
gentamycin (50 mg/ml). For drug treatment, the identical medium supplemented with 2% FCS was used.
All dengue viruses were purchased from the European Collection of Cell Cultures (ECACC).
ATP is a marker for cell viability because it is present in all metabolically active cells and the concentration declines very rapidly when the cells undergo necrosis or apoptosis. The ATPlite 1 step assay system is based on the production of light caused by the reaction of ATP with added luciferase and D-luciferin.
This is illustrated in the following reaction scheme:
ATP + D-Luciferin + 02 + (Mg 2W + Luciferase enyme) 9 Oxyluciferin +
+ AMP + BBi + C02 + Light The emitted light is proportional to the ATP concentration within certain limits.
Materials and methods 1. Cells and viruses Vero cells (African green monkey kidney cells) were purchased from the 3o European Collection of Cell Cultures (ECACC) and cultured in Eagle's Minimum Essential Medium (MEM; Invitrogen) supplemented with 10% fetal calf serum (FCS; Cambrex, Belgium), 2 mM L-glutamine, and 0.04%
gentamycin (50 mg/ml). For drug treatment, the identical medium supplemented with 2% FCS was used.
All dengue viruses were purchased from the European Collection of Cell Cultures (ECACC).
-6-2. Virus stocks and titrations Dengue virus stocks were prepared using the Vero cells and titrated by measuring the 50% tissue culture infectious dose (TCID50), the virus stock dilution that produced CPE in 50% of the cells at endpoint.
3. Antiviral assays (dengue serotype 2) pl of Vero cells (1500 cells/well) were added to a 384-well white plate containing 10 pl of four-fold serially diluted testing compound in cell culture medium with 2% FCS. 15 pl of virus stock was then added to each well at a 1o MOI of 0.1. Cell controls received only cells and medium, while virus controls received virus but no test compound. Plates were incubated at 37 C until the viral CPE in the virus control wells reached -100% (5-6 days). ATPLite (Perkin Elmer) was added to all wells according to the supplier's instructions.
Briefly, 40 pl of the reconstituted lyophilized substrate solution was added to each well.
15 The plate was shaken at 700 rpm for 2 minutes and the luminescence was measured using a Viewlux apparatus (Perkin Elmer) by taking a 0.1-0.5-second integrated reading of each test plate. The results were expressed as EC50 values defined as the concentration of compound achieving 50%
inhibition of the virus-reduced luminescence signals as compared with the uninfected cell control. The signal-to-noise ratio of an assay is the ratio between the mean luminescent signals of the cell controls and the virus controls. The dynamic range is defined as the ratio between the signals at the last (maximal signal) and first point in the linear range of the dose-response curve.
4. Cytotoxicity assay To test for cytotoxicity, cells were incubated with serial compound dilutions as described above but in the absence of virus. The 50% cytotoxic concentration (CC50) was determined by comparing the luminescent signal of compound treated wells with cell control wells.
5. Assay reproducibility Intra-assay reproducibility was measured by performing each experiment in three identical plates with each concentration of drug in triplicate. Inter-assay reproducibility was measured by performing three independent experiments at different times under the same experimental conditions.
3. Antiviral assays (dengue serotype 2) pl of Vero cells (1500 cells/well) were added to a 384-well white plate containing 10 pl of four-fold serially diluted testing compound in cell culture medium with 2% FCS. 15 pl of virus stock was then added to each well at a 1o MOI of 0.1. Cell controls received only cells and medium, while virus controls received virus but no test compound. Plates were incubated at 37 C until the viral CPE in the virus control wells reached -100% (5-6 days). ATPLite (Perkin Elmer) was added to all wells according to the supplier's instructions.
Briefly, 40 pl of the reconstituted lyophilized substrate solution was added to each well.
15 The plate was shaken at 700 rpm for 2 minutes and the luminescence was measured using a Viewlux apparatus (Perkin Elmer) by taking a 0.1-0.5-second integrated reading of each test plate. The results were expressed as EC50 values defined as the concentration of compound achieving 50%
inhibition of the virus-reduced luminescence signals as compared with the uninfected cell control. The signal-to-noise ratio of an assay is the ratio between the mean luminescent signals of the cell controls and the virus controls. The dynamic range is defined as the ratio between the signals at the last (maximal signal) and first point in the linear range of the dose-response curve.
4. Cytotoxicity assay To test for cytotoxicity, cells were incubated with serial compound dilutions as described above but in the absence of virus. The 50% cytotoxic concentration (CC50) was determined by comparing the luminescent signal of compound treated wells with cell control wells.
5. Assay reproducibility Intra-assay reproducibility was measured by performing each experiment in three identical plates with each concentration of drug in triplicate. Inter-assay reproducibility was measured by performing three independent experiments at different times under the same experimental conditions.
-7-Table: the EC50 values of three (3) selected compounds EC50 (PM) Exp. # 1 Exp. # 2 Exp. # 3 Exp. # 4 Exp. # 5 Exp. # 6 Exp. # 7 Ribavirin 51.99 53.80 43.76 42.38 47.71 68.98 67.47 2'-C-methylcytidine 13.49 14.64 10.28 10.43 6.73 14.03 17.41 6-Azauridine 5.52 4.85 3.74 4.26 4.60 3.81 5.14 The above demonstrates that the method according to the invention can be used to test for the selection of compounds which inhibit dengue virus.
6. Antiviral assays (dengue serotypes 1, 3, and 4) The antiviral assays for dengue serotypes 1, 3, and 4 are similar to that of dengue serotype 2 except Huh7.5 cells (1000 cells/well) were used. The virus 1o input for dengue serotype 1 (strain TC974) and serotype 4 (strain H241) is MOI
of 5, for dengue serotype 3 (strain H87) is MOI of 1. The incubation time is 5 days.
7. Comparison with dye uptake assay:
Cytopathic effect inhibition assays usually employ dye uptake readouts, e.g.
neutral red and MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide). The major drawbacks of such colorimetric readouts are low throughput, low dynamic range, and a low signal-to-noise ratio. For dengue virus, although 100% cytopathic effect was evident in infected cells, the presence of cell debris causes a high background, resulting in an extremely low signal-to-noise ratio and dynamic range. This renders the dye uptake assay unsuitable for dengue CPE inhibition assay. To overcome these disadvantages, an alternative assay using the ATP/luminescence readout was developed and validated. In comparison with dye uptake based assays, assays with ATP/luminescence based readout give unexpectedly a larger dynamic range and better signal-to-noise ratio (20-30 folds, see Figure 1). Further advantages of such assays are their high throughput and homogenous nature (mix and measure). As screening programs based on traditional CPE readouts are often hampered by problematic signal-to-noise ratios and low throughput, changing the end-point to a luminescent readout may has a significant impact on drug discovery.
6. Antiviral assays (dengue serotypes 1, 3, and 4) The antiviral assays for dengue serotypes 1, 3, and 4 are similar to that of dengue serotype 2 except Huh7.5 cells (1000 cells/well) were used. The virus 1o input for dengue serotype 1 (strain TC974) and serotype 4 (strain H241) is MOI
of 5, for dengue serotype 3 (strain H87) is MOI of 1. The incubation time is 5 days.
7. Comparison with dye uptake assay:
Cytopathic effect inhibition assays usually employ dye uptake readouts, e.g.
neutral red and MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide). The major drawbacks of such colorimetric readouts are low throughput, low dynamic range, and a low signal-to-noise ratio. For dengue virus, although 100% cytopathic effect was evident in infected cells, the presence of cell debris causes a high background, resulting in an extremely low signal-to-noise ratio and dynamic range. This renders the dye uptake assay unsuitable for dengue CPE inhibition assay. To overcome these disadvantages, an alternative assay using the ATP/luminescence readout was developed and validated. In comparison with dye uptake based assays, assays with ATP/luminescence based readout give unexpectedly a larger dynamic range and better signal-to-noise ratio (20-30 folds, see Figure 1). Further advantages of such assays are their high throughput and homogenous nature (mix and measure). As screening programs based on traditional CPE readouts are often hampered by problematic signal-to-noise ratios and low throughput, changing the end-point to a luminescent readout may has a significant impact on drug discovery.
8 PCT/EP2010/056483 8. The accuracy of the assay:
The table listed the EC50s of the reference compounds and the number of measurements.
Compound EC50 (pM) # data Ribavirin 52.97 10.21 53 2'-C-meth lc tidine 12.62 3.32 54 6-Azauridine 4.53 0.83 42 Interferon-a 861.2 IU/ml 427.11 30 The robustness of the assay was determined by up to 24 measurements with variable operators, experiments, plate productions and virus stocks.
The table listed the EC50s of the reference compounds and the number of measurements.
Compound EC50 (pM) # data Ribavirin 52.97 10.21 53 2'-C-meth lc tidine 12.62 3.32 54 6-Azauridine 4.53 0.83 42 Interferon-a 861.2 IU/ml 427.11 30 The robustness of the assay was determined by up to 24 measurements with variable operators, experiments, plate productions and virus stocks.
9. Library screening:
1o Using this HTS assay, a total of 150,000 compounds from different libraries were screened. The hit rate is -0.83% (SI>4).
1o Using this HTS assay, a total of 150,000 compounds from different libraries were screened. The hit rate is -0.83% (SI>4).
10. Precision of the assay:
The precision of the assay is determined by measuring the variability of the EC50 values of the reference compounds A, B, C and D and shown in Figure 2.
= Within assay variability = Repeatibility (within-day variability) = Reproducibility (between-day variability)
The precision of the assay is determined by measuring the variability of the EC50 values of the reference compounds A, B, C and D and shown in Figure 2.
= Within assay variability = Repeatibility (within-day variability) = Reproducibility (between-day variability)
Claims (8)
1. Method for identifying inhibitors against dengue viruses serotypes 1, 2, 3 or 4 by screening chemical compounds or chemical compound libraries comprising:
a) bringing about 1000 to 2000 Vero cells or Huh 7.5 cells into contact with a chemical compound, b) adding dengue virus to said cells and chemical compound of step a), c) incubating said cells, chemical compound and virus of step b) at 37°C
until viral cytopathic effect (CPE) in the virus control reaches about 100%, d) adding luciferase enzyme and luciferase substrate to the cells, compound, virus, e) measuring the luminescence and calculate the EC50 value which is a measure for the inhibitory activity of the compound against dengue virus.
a) bringing about 1000 to 2000 Vero cells or Huh 7.5 cells into contact with a chemical compound, b) adding dengue virus to said cells and chemical compound of step a), c) incubating said cells, chemical compound and virus of step b) at 37°C
until viral cytopathic effect (CPE) in the virus control reaches about 100%, d) adding luciferase enzyme and luciferase substrate to the cells, compound, virus, e) measuring the luminescence and calculate the EC50 value which is a measure for the inhibitory activity of the compound against dengue virus.
2. Method according to claim 1 wherein the dengue virus is Dengue Virus subtype 2 and the cells are about 1500 Vero cells.
3. Method according to claim 1 wherein the dengue virus is Dengue Virus subtype 1, 3 or 4 and the cells are Huh 7.5 cells.
4. Method according to claim 1 or 2 wherein the dengue virus has a multiplicity of infection (MOI) of 0.1, 0.5 or 1.0, preferably 0.1.
5. Method according to claim 1 or 3 wherein the dengue virus has a multiplicity of infection (MOI) between 1.0 and 10.0, preferably 1.0 or 5Ø
6. Method according to claim 1-5 wherein step c) is about 5 or 6 days.
7. Method according to any of the claims 1-6 wherein the luciferase substrate is D-Luciferin.
8. Method according to any of the claims 1-7 wherein the method is performed in a high throughput mode.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09159994.4 | 2009-05-12 | ||
| EP09159994 | 2009-05-12 | ||
| PCT/EP2010/056483 WO2010130748A1 (en) | 2009-05-12 | 2010-05-11 | Method for identifying inhibitors against dengue virus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2760348A1 true CA2760348A1 (en) | 2010-11-18 |
| CA2760348C CA2760348C (en) | 2017-10-03 |
Family
ID=40679474
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2760348A Active CA2760348C (en) | 2009-05-12 | 2010-05-11 | Method for identifying inhibitors against dengue virus |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20120058920A1 (en) |
| EP (1) | EP2430444B1 (en) |
| AU (1) | AU2010247461B2 (en) |
| CA (1) | CA2760348C (en) |
| ES (1) | ES2456365T3 (en) |
| WO (1) | WO2010130748A1 (en) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL1010224C2 (en) * | 1998-09-30 | 2000-03-31 | Packard Biosciene B V | Method for detecting ATP. |
| EP2292802B1 (en) * | 2001-05-22 | 2015-01-14 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses |
| CA2532084A1 (en) * | 2003-07-11 | 2005-02-03 | Oregon Health And Science University | Methods of treatment and diagnosis using modulators of virus-induced cellular gene sequences |
| CN101040054A (en) * | 2004-07-02 | 2007-09-19 | 普罗美加公司 | System for the extraction and detection of microbial atp |
| WO2009016831A1 (en) * | 2007-08-02 | 2009-02-05 | Osaka University | Methods of identifying agents for treating dengue hemorrhagic fever |
-
2010
- 2010-05-11 ES ES10721437.1T patent/ES2456365T3/en active Active
- 2010-05-11 WO PCT/EP2010/056483 patent/WO2010130748A1/en active Application Filing
- 2010-05-11 EP EP10721437.1A patent/EP2430444B1/en active Active
- 2010-05-11 AU AU2010247461A patent/AU2010247461B2/en not_active Ceased
- 2010-05-11 CA CA2760348A patent/CA2760348C/en active Active
- 2010-05-11 US US13/319,724 patent/US20120058920A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010130748A1 (en) | 2010-11-18 |
| US20120058920A1 (en) | 2012-03-08 |
| EP2430444B1 (en) | 2014-01-08 |
| AU2010247461A1 (en) | 2011-11-17 |
| AU2010247461B2 (en) | 2015-09-03 |
| CA2760348C (en) | 2017-10-03 |
| ES2456365T3 (en) | 2014-04-22 |
| EP2430444A1 (en) | 2012-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bullard-Feibelman et al. | The FDA-approved drug sofosbuvir inhibits Zika virus infection | |
| Noble et al. | Strategies for development of dengue virus inhibitors | |
| Xie et al. | Inhibition of dengue virus by targeting viral NS4B protein | |
| Dosch et al. | SARS coronavirus spike protein-induced innate immune response occurs via activation of the NF-κB pathway in human monocyte macrophages in vitro | |
| Zou et al. | Development and characterization of a stable luciferase dengue virus for high-throughput screening | |
| Puig-Basagoiti et al. | Triaryl pyrazoline compound inhibits flavivirus RNA replication | |
| CN113009154B (en) | Novel one-step method coronavirus neutralizing antibody magnetic microsphere detection kit and application thereof | |
| Tuiskunen et al. | Phenotypic and genotypic characterization of dengue virus isolates differentiates dengue fever and dengue hemorrhagic fever from dengue shock syndrome | |
| Bielefeldt-Ohmann | Analysis of antibody-independent binding of dengue viruses and dengue virus envelope protein to human myelomonocytic cells and B lymphocytes | |
| Wang et al. | Quantitative competitive reverse transcription-PCR for quantification of dengue virus RNA | |
| Hanson et al. | Identification and analysis of inhibitors targeting the hepatitis C virus NS3 helicase | |
| Shen et al. | Generation of a recombinant classical swine fever virus stably expressing the firefly luciferase gene for quantitative antiviral assay | |
| Gyawali et al. | Diagnosis of dengue: strengths and limitations of current techniques and prospects for future improvements | |
| Song et al. | A novel reporter system for neutralizing and enhancing antibody assay against dengue virus | |
| Rasulova et al. | A high-throughput yellow fever neutralization assay | |
| Fernandez-Sainz et al. | Mutations in classical swine fever virus NS4B affect virulence in swine | |
| CN101405295A (en) | Hepatitis C virus variants | |
| Puig-Basagoiti et al. | Identification and characterization of inhibitors of West Nile virus | |
| Itakura et al. | A cloned classical swine fever virus derived from the vaccine strain GPE− causes cytopathic effect in CPK-NS cells via type-I interferon-dependent necroptosis | |
| Lim et al. | Vero cell-derived inactivated West Nile (WN) vaccine induces protective immunity against lethal WN virus infection in mice and shows a facilitated neutralizing antibody response in mice previously immunized with Japanese encephalitis vaccine | |
| Way et al. | A novel SUMOylation site in the influenza a virus NS1 protein identified with a highly sensitive FRET assay | |
| Hou et al. | Development of a coxsackievirus A16 neutralization test based on the enzyme-linked immunospot assay | |
| Ackermann-Gäumann et al. | Standardized focus assay protocol for biosafety level four viruses | |
| CA2760348C (en) | Method for identifying inhibitors against dengue virus | |
| Quintana et al. | A direct high-throughput in cell-ELISA for measuring infectivity of cytopathic and non-cytopathic bovine viral diarrhoea virus strains applied to the assessment of antiviral activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20150504 |